NASDAQ:BSTC BioSpecifics Technologies (BSTC) Stock Price, News & Analysis → Elon’s New Device is About to Shock the World (From InvestorPlace) (Ad) Free BSTC Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$88.53▼$88.5350-Day Range$88.22▼$88.5352-Week Range$42.00▼$89.15VolumeN/AAverage Volume61,105 shsMarket Capitalization$650.25 millionP/E Ratio37.51Dividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Ad InvestorPlaceCrypto Pioneer Says: “The last crypto bull market has begun.”Right now, there’s over $6 trillion in potential investment money waiting on the sidelines. That means this crypto bull market has a lot more room to run before it comes close to being a bubble.Click here if you’d like to learn more about these five cryptos… About BioSpecifics Technologies Stock (NASDAQ:BSTC)BioSpecifics Technologies Corp., a biopharmaceutical company, develops an injectable collagenase clostridium histolyticum for various indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX and Xiapex brands. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis, human lipoma, and uterine fibroids. The company has a development and license agreement with Endo Global Ventures. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Wilmington, Delaware.Read More Ad InvestorPlaceCrypto Pioneer Says: “The last crypto bull market has begun.”Right now, there’s over $6 trillion in potential investment money waiting on the sidelines. That means this crypto bull market has a lot more room to run before it comes close to being a bubble.Click here if you’d like to learn more about these five cryptos… BSTC Stock News HeadlinesMarch 21, 2023 | bizjournals.comSilicon Valley Technology NewsSee More Headlines Company Calendar Last Earnings11/14/2020Today5/19/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:BSTC CUSIP09093110 CIK875622 Webwww.biospecifics.com Phone302-842-8450FaxN/AEmployees7Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$3.33 Trailing P/E Ratio37.51 Forward P/E Ratio61.91 P/E GrowthN/ANet Income$24.47 million Net Margins47.43% Pretax MarginN/A Return on Equity14.81% Return on Assets14.46% Debt Debt-to-Equity RatioN/A Current Ratio66.24 Quick Ratio66.24 Sales & Book Value Annual Sales$38.19 million Price / Sales17.03 Cash Flow$3.38 per share Price / Cash Flow26.18 Book Value$18.42 per share Price / Book4.81Miscellaneous Outstanding Shares7,345,000Free FloatN/AMarket Cap$650.25 million OptionableNot Optionable Beta0.24 Key ExecutivesDr. Ronald Law J.D. (Age 67)Ph.D., Sr. VP of Bus. Devel. Comp: $487.38kMr. Joseph Truitt (Age 55)CEO & Director Mr. Patrick C. Hutchison (Age 61)Chief Financial Officer Mr. Alex MonteithSr. VP & Chief Bus. OfficerCarl A. ValensteinCorp. Sec.Key CompetitorsSinovac BiotechNASDAQ:SVAStemline TherapeuticsNASDAQ:STMLAkouosNASDAQ:AKUSLexicon PharmaceuticalsNASDAQ:LXRXOPKO HealthNASDAQ:OPKView All Competitors BSTC Stock Analysis - Frequently Asked Questions How were BioSpecifics Technologies' earnings last quarter? BioSpecifics Technologies Corp. (NASDAQ:BSTC) posted its quarterly earnings results on Saturday, November, 14th. The biopharmaceutical company reported $0.89 earnings per share for the quarter, topping analysts' consensus estimates of $0.19 by $0.70. The biopharmaceutical company earned $11.26 million during the quarter, compared to the consensus estimate of $5.46 million. BioSpecifics Technologies had a trailing twelve-month return on equity of 14.81% and a net margin of 47.43%. What other stocks do shareholders of BioSpecifics Technologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other BioSpecifics Technologies investors own include AbbVie (ABBV), NVIDIA (NVDA), Pfizer (PFE), Biogen (BIIB), Johnson & Johnson (JNJ), Horizon Therapeutics Public (HZNP), Inovio Pharmaceuticals (INO), Intel (INTC), Bristol-Myers Squibb (BMY) and CRISPR Therapeutics (CRSP). This page (NASDAQ:BSTC) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaElon’s New Device is About to Shock the WorldInvestorPlaceBiden Nomination CANCELED?The Freeport SocietyShocking: One AI startup's revenue could surge 4,735%Manward PressUrgent Nvidia WarningAltimetry"The Biggest Drug Ever" Is ComingBehind the MarketsProtect Your Bank Account Before It’s Too LateWeiss RatingsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist My Default Watchlist Adding BioSpecifics Technologies Corp. You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.